Roughly five to ten percent of all cancers trace back to inherited genetic mutations that dramatically raise a person’s lifetime risk, and identifying those mutations now shapes not only screening and prevention but also which drugs a patient receives. The field of cancer genetics sits at the intersection of two practical questions: who is predisposed, and once a tumor appears, how can its specific genetic profile guide treatment? The answers have grown far more precise over the past two decades, though they remain uneven across populations and imperfect in ways that matter for real patients.
How Inherited Mutations Set the Stage
The foundational concept in hereditary cancer is the “two-hit” model. In its simplest form, a tumor-suppressor gene needs both of its copies knocked out before it stops doing its job. People who inherit one damaged copy from a parent already have the first hit in every cell of their body. They only need one more spontaneous mutation in the remaining copy for that cell to start growing unchecked. People without an inherited mutation need both hits to occur by chance in the same cell, which is far less likely and typically happens later in life.
The classic example is the RB1 gene in retinoblastoma, where both hereditary and non-hereditary forms involve the loss of both gene copies, but the hereditary form shows up earlier and often in both eyes because that first hit is already present at birth.1PubMed Central. Hereditary cancer: two hits revisited This same logic has since been confirmed genome-wide. An analysis of roughly 10,000 tumor samples used a method called ALFRED to test the two-hit hypothesis across many genes simultaneously, finding that tumor-suppressor genes consistently showed loss of the remaining normal copy in people who carried a damaging inherited variant.2Nature Communications. Systematic discovery of germline cancer predisposition genes through the identification of somatic second hits
Not All Carriers Face the Same Risk
One of the most important developments in cancer genetics is the recognition that a single high-risk mutation does not act in isolation. Your overall genetic background, sometimes measured as a polygenic score combining the effects of many common low-risk variants, substantially modifies how dangerous a mutation like BRCA1 or BRCA2 turns out to be for you personally.
A large study using the UK Biobank found that breast cancer risk among BRCA1 or BRCA2 carriers ranged from about 13% to 76% probability of developing disease by age 75, depending on where the carrier fell in the distribution of common genetic variants. Carriers in the lowest fifth of polygenic risk had about a 2.4-fold increased risk compared to non-carriers with average scores, while those in the highest fifth faced nearly a 7-fold increase.3Nature Communications. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions This is a strikingly wide range. It means two people carrying the same BRCA2 mutation can have very different actual chances of developing cancer, which has real implications for how aggressively doctors recommend surveillance or preventive surgery.
Major Hereditary Cancer Syndromes
Several well-characterized syndromes account for most known hereditary cancer cases. BRCA1 and BRCA2 mutations are the most widely recognized, primarily associated with breast and ovarian cancer but also linked to pancreatic and prostate cancers. Lynch syndrome, caused by inherited defects in DNA mismatch repair genes (MLH1, MSH2, MSH6, or PMS2), predisposes carriers to colorectal, endometrial, ovarian, and several other cancer types.4PubMed Central. An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome Li-Fraumeni syndrome, driven by inherited TP53 mutations, is rarer but especially aggressive, predisposing to sarcomas, brain tumors, breast cancer, leukemia, and adrenal cancers. Evidence also supports early-onset gastric cancer as part of the Li-Fraumeni spectrum, which has prompted recommendations for regular endoscopic screening in these families.5PubMed Central. Gastric cancer in individuals with Li-Fraumeni syndrome
What ties these syndromes together is that they all involve loss of function in genes responsible for maintaining DNA integrity. BRCA genes help repair double-strand DNA breaks. Mismatch repair genes fix small errors during DNA copying. TP53 serves as a master checkpoint, halting cell division when DNA damage is detected. When any of these safety nets has a hole in it from birth, the accumulation of further errors accelerates.
What Genetic Testing Actually Finds
Broader genetic testing panels have increased the chance of finding something clinically meaningful. In a study of a large cancer cohort that underwent expanded testing, about 17% of patients carried a clearly harmful variant in a cancer predisposition gene. The rates varied by cancer type: roughly a quarter of ovarian cancer patients had such a variant, compared to about 15–20% for breast, colorectal, pancreatic, and prostate cancers. Interestingly, about 8% of patients with these five common cancers carried harmful variants in genes not previously associated with their particular cancer, and nearly 1% of those variants conferred high risk for a different cancer type entirely.6PubMed Central. Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients That last finding underscores why multi-gene panels have value beyond confirming the expected diagnosis.
The catch is that broader testing also finds more ambiguous results. Variants of uncertain significance, or VUS, are genetic changes where it is unclear whether they actually increase cancer risk. The proportion of VUS results is growing as testing expands to more patients and more genes, and a misinterpreted VUS can lead to unnecessary surgeries or inappropriate reassurance for family members.7PubMed Central. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance Laboratories have developed classification programs to reclassify VUS over time as more data accumulates, but the process is slow and sometimes leaves patients in limbo for years.8PubMed. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes
How Inherited Mutations Guide Treatment
Knowing a tumor’s genetic roots does more than quantify risk. It increasingly determines which drugs will work best. The clearest example is PARP inhibitors in BRCA-mutated cancers. BRCA1 and BRCA2 are essential for repairing double-strand DNA breaks through a process called homologous recombination. When a tumor has lost both copies of one of these genes, it becomes reliant on a backup repair pathway involving PARP enzymes. Block PARP with a drug, and the tumor cells accumulate so much DNA damage they die, while normal cells with one working BRCA copy survive.9PubMed Central. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings This concept, synthetic lethality, has transformed treatment for BRCA-associated breast and ovarian cancers.10PubMed Central. PARP inhibitors: Synthetic lethality in the clinic
Lynch syndrome cancers offer a different treatment opportunity. Because mismatch repair deficiency causes these tumors to accumulate enormous numbers of small mutations, the resulting proteins look foreign to the immune system. This makes Lynch-associated tumors, and mismatch-repair-deficient tumors more broadly, highly responsive to immune checkpoint inhibitors that unleash the body’s T cells against cancer.4PubMed Central. An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome 11The Oncologist. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Targeted Therapy Beyond Inherited Mutations
Not all precision oncology hinges on inherited mutations. Many of the most successful targeted therapies exploit mutations that arise spontaneously in the tumor itself. Non-small-cell lung cancer has become the poster child for this approach. Tumors with EGFR mutations or ALK rearrangements respond dramatically to specific tyrosine kinase inhibitors, often outperforming conventional chemotherapy.12PubMed. Targeted therapy for lung cancer: Beyond EGFR and ALK The list of actionable targets in lung cancer alone now includes BRAF V600E mutations, KRAS G12C mutations, MET alterations, and RET and NTRK rearrangements, each with approved drugs.13PubMed. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
The distinction between inherited and somatic (tumor-acquired) mutations matters practically. An inherited BRCA mutation means every cell in the body carries it, so the patient’s relatives may also carry it, and the finding guides both treatment and family screening. A somatic EGFR mutation in a lung tumor says nothing about the patient’s children or siblings; it only guides drug selection for that particular cancer.
Tumor Mutational Burden and Immunotherapy
A tumor’s overall mutation count, often called tumor mutational burden (TMB), has emerged as a potential predictor of how well immunotherapy will work. The logic is straightforward: more mutations mean more abnormal proteins on the tumor’s surface, giving the immune system more targets to attack. Higher TMB generally correlates with better responses to immune checkpoint inhibitors.14PubMed Central. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives In metastatic melanoma, patients with high TMB had a median progression-free survival of nearly 39 months compared to under 4 months for those with low TMB.15npj Precision Oncology. Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma
But TMB is not a universal crystal ball. A study examining TMB across multiple cancer types found that it predicted immunotherapy response well in cancers where high mutation counts correlated with immune cell infiltration, such as melanoma and lung cancer. In other cancer types, including breast and prostate, high TMB tumors actually had lower response rates to checkpoint blockade than low TMB tumors.16Annals of Oncology. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types The tumor’s immune environment matters as much as its raw mutation count, which is why oncologists are moving toward combining multiple biomarkers rather than relying on any single measure.
When Targeted Treatments Stop Working
Even the most effective targeted therapies eventually face resistance. Tumors are genetically unstable, and among the billions of cells in a cancer, there are almost always some with pre-existing or newly acquired mutations that let them survive the drug. Common resistance mechanisms include new mutations in the drug’s target that prevent it from binding, activation of alternative signaling pathways (particularly the MAPK and PI3K/Akt pathways) that bypass the blocked route, and modifications to the drug target itself.17PubMed Central. Acquired resistance to molecularly targeted therapies for cancer This is why many patients who initially respond well to a targeted drug eventually see their cancer progress. Researchers are developing combination strategies and next-generation drugs designed to overcome these escape routes, and liquid biopsies that detect circulating tumor DNA can help catch resistance mutations early, sometimes before the cancer visibly progresses on scans.18PubMed Central. Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
Pharmacogenomics and Drug Tolerance
Genetics shapes not just which drugs target a tumor but also how safely a patient can tolerate standard chemotherapy. One well-established example involves the DPYD gene, which encodes the enzyme responsible for breaking down fluoropyrimidine drugs, a backbone of treatment for colorectal, breast, and several other cancers. People who carry certain DPYD variants process these drugs too slowly, leading to dangerous buildup and severe toxicity. Pre-treatment screening for DPYD variants allows doctors to reduce the dose before the first infusion, preventing life-threatening complications.19PubMed Central. Implementation of pharmacogenetic testing in oncology: DPYD -guided dosing to prevent fluoropyrimidine toxicity in British Columbia
DPYD is not the only gene that matters. Variants in UGT1A1, TPMT, and NUDT15 affect the metabolism of other commonly used cancer drugs, and pre-treatment screening for all of these offers a validated way to adjust dosing before problems arise.20Journal of Pharma Insights and Research. Pharmacist-Led Implementation of Oncology Pharmacogenomic Testing of DPYD, UGT1A1, TPMT, and NUDT15 in Community and Rural Hospitals Adoption of pharmacogenomic testing in oncology has been uneven, but it is gradually becoming standard practice, particularly in Europe where DPYD testing before fluoropyrimidine therapy is now mandated in several countries.
Gaps in Who Benefits From Precision Oncology
The promise of genetically guided cancer treatment has not reached everyone equally. Most large genomic databases and clinical trials have been built on data from people of European ancestry, which creates a real problem. Biomarker-based eligibility for precision therapies differs by genetic ancestry, partly because lower-frequency variants enriched in underrepresented populations may never have been studied, and partly because more aggressive cancer subtypes that are more common in certain populations have been underpowered in research.21JAMA Oncology. Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies The result is that a targeted drug may exist for a mutation common in one population while a different population’s characteristic mutations remain unstudied.
Access barriers compound the science gap. Payment assistance programs have helped reduce financial obstacles to genetic testing, but access to genetic counseling remains a bottleneck, particularly in underserved communities.22PubMed Central. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings Without counseling, patients may not understand their results, and family members who could benefit from cascade testing may never be reached.
Cascade Testing and Why Families Fall Through the Cracks
When someone is found to carry a hereditary cancer mutation, their close relatives have a 50% chance of carrying the same variant. “Cascade testing” refers to the process of identifying and testing those at-risk family members, and it is one of the highest-value interventions in all of cancer prevention. Yet uptake is surprisingly low. A study examining barriers to cascade testing in families with hereditary breast and ovarian cancer found that even relatives who expressed interest in getting tested often did not follow through, citing fear of a positive result, concern about genetic discrimination, and a belief that the mutation was not relevant to their own health.23PubMed Central. Barriers to completion of cascade genetic testing: How can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
The fear of genetic discrimination is a recurring barrier and not entirely unfounded, despite legal protections. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from using genetic information against people. But awareness of GINA among both patients and doctors remains low. A survey of clinicians found that while 96% viewed genetic testing as beneficial, 75% believed patients would decline it out of fear of discrimination, and over 60% of those clinicians were themselves unaware of federal laws prohibiting health insurance discrimination based on genetic results.24Genetics in Medicine. Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians GINA also does not cover life insurance, disability insurance, or long-term care insurance, which are gaps that can feel quite real to a healthy 30-year-old weighing whether to find out if they carry a BRCA mutation.25PubMed Central. Genetic information, non-discrimination, and privacy protections in genetic counseling practice Among Black women specifically, lack of confidence in GINA has been identified as a barrier to seeking genetic counseling and testing, layered on top of broader institutional distrust.26PubMed Central. Black Women’s Confidence in the Genetic Information Nondiscrimination Act
Non-Coding Variants and the Expanding Map of Risk
Most genetic testing still focuses on the protein-coding regions of known cancer genes, but the majority of inherited variants actually sit in non-coding parts of the genome, regions that do not directly encode proteins but regulate when and how much of a gene gets turned on. These non-coding variants can affect the regulation of tumor-suppressor genes and oncogenes in cancer-specific ways, and inherited non-coding changes can predispose someone to cancer decades before the disease appears.27PubMed Central. Non-Coding Variants in Cancer: Mechanistic Insights and Clinical Potential for Personalized Medicine
A recent case-control study of over 11,000 participants examined non-coding regions of BRCA1, BRCA2, and PALB2, three key breast cancer genes. Nearly half of breast cancer cases carried at least one rare non-coding variant in these genes, and the enrichment was strongest for triple-negative breast cancer, particularly for BRCA1 variants. Functional laboratory experiments confirmed that some deep intronic variants created abnormal splice sites that disrupted normal gene expression.28PubMed Central. Investigating the contribution of rare non-coding variants in BRCA1, BRCA2 and PALB2 to hereditary breast cancer Epigenetic alterations, changes in gene regulation that do not involve the DNA sequence itself, add another layer of complexity, with growing evidence that inherited epimutations can silence cancer-protective genes without any detectable mutation in the gene’s coding sequence.29PubMed Central. Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research
This research sits at the frontier. Clinically, we cannot yet screen for most non-coding risk variants with confidence. But it helps explain a frustrating clinical scenario: families with clear patterns of hereditary cancer where standard genetic testing comes back negative. Some of those families likely harbor pathogenic variants hiding in non-coding territory that current panels simply do not look at. As sequencing costs drop and interpretation tools improve, including AI-driven platforms designed to classify both coding and non-coding variants systematically,30PubMed Central. CancerVar: An artificial intelligence-empowered platform for clinical interpretation of somatic mutations in cancer the diagnostic yield of cancer genetic testing is likely to keep climbing, bringing answers to families who currently have none.